Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mark A. Sitarik"'
Autor:
Charles White, Sheetal Sheth, J. Russell Hoverman, Aimee Ginsburg, Janet L. Espirito, Roy A. Beveridge, Barry Don Brooks, Michael Kolodziej, Roger T. Anderson, Marcus A. Neubauer, Debra A. Patt, Jody S. Garey, Mark A. Sitarik
Cancer costs are increasing at an unprecedented rate. Key cost drivers include chemotherapy, hospital admissions/emergency room visits, and aggressive end-of-life care. We sought to evaluate these costs in a commercial payer population in collaborati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba2133e619a1c1455cfdc945f80ada6
https://europepmc.org/articles/PMC3170062/
https://europepmc.org/articles/PMC3170062/
Autor:
Eric Scott Palmer, Marcus A. Neubauer, Scott Kruger, Margaret McGuinness, Jody S. Garey, Mark A. Sitarik, Sheetal Sheth, Thomas Flynn, Michael A. Willen, David C. Chang, Leslie T. Busby, Linda Frisk, Alison Fetter, Roger T. Anderson, Nancy J. Egerton, Eileen B. Herbeck, Jan Merriman, Roy A. Beveridge, Michael A. Kolodziej, Aimee Ginsburg
US Oncology uses regimen order sets in clinical practice to treat patients. However, the process to assure accuracy and upkeep of these order sets has not been described. The purpose of this project was to evaluate the regimens housed in the electron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a26217a0a0b3aa7504a7d41f20435c85
https://europepmc.org/articles/PMC3140457/
https://europepmc.org/articles/PMC3140457/
Autor:
Debra A. Patt, Asif Ahmad, Roy A. Beveridge, Madeline Nubie, Denise R. Kazzaz, Leslie T. Busby, Aimee Ginsburg Arlen, Mark A. Sitarik
Publikováno v:
Journal of Clinical Oncology. 30:294-294
294 Background: Electronic health records (EHR) provide opportunities for quality enhancements at various points in care. It can support electronic orders, meaningful use, progress notes, medication and allergy data, electronic prescribing, and vital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e6d1b20915324f8645367164df27d9e
https://doi.org/10.1200/jco.2012.30.34_suppl.294
https://doi.org/10.1200/jco.2012.30.34_suppl.294
Autor:
Yunfei Wang, Neelima Denduluri, Linda D. Bosserman, Roy A. Beveridge, Janet L. Espirito, Leslie T. Busby, Barry Don Brooks, Mark A. Sitarik, Kimberly A. Bergstrom, J. Russell Hoverman, Lina Asmar, Brian Turnwald, Marcus A. Neubauer, Jody S. Garey, Debra A. Patt, Ian D. Schnadig, Thomas H. Cartwright, William E. Winter
Publikováno v:
Journal of Clinical Oncology. 30:62-62
62 Background: AML and MDS complicate adjuvant CT in BC. Incidence Rates of MDS/AML with pegfilgrastim (PGCSF) use and newer adjuvant regimens in large patient (pt) populations are not widely characterized. Methods: We queried the iKnowMed electronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dde3995d1cb5f830ab93301510bcb63c
https://doi.org/10.1200/jco.2012.30.27_suppl.62
https://doi.org/10.1200/jco.2012.30.27_suppl.62
Autor:
Leslie T. Busby, Debra A. Patt, Marcus A. Neubauer, J. Russell Hoverman, Barry Don Brooks, Mark A. Sitarik, Thomas H. Cartwright, Brian Turnwald, Roy A. Beveridge, Janet L. Espirito, Michael A. Kolodziej
Publikováno v:
Journal of Clinical Oncology. 30:6109-6109
6109 Background: Adjuvant breast cancer (BC) chemotherapy (CT) treatment has evolved over time due to improved understanding of risk conveyed by pathology and patient (pt) characteristics, as well as emergence of new and mature data for survival and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a63816249620293b061d69d212cf7a00
https://doi.org/10.1200/jco.2012.30.15_suppl.6109
https://doi.org/10.1200/jco.2012.30.15_suppl.6109
Autor:
R. W. Anderson, John Russell Hoverman, Brian Turnwald, Barry Don Brooks, Roy A. Beveridge, Aimee Ginsburg, Michael Kolodziej, Janet L. Espirito, Greg C. Nelson, Marcus A. Neubauer, Thomas H. Cartwright, Mark A. Sitarik, M. Clayton, Sheetal Sheth, Jody S. Garey, Leslie T. Busby, Debra A. Patt
Publikováno v:
Journal of Clinical Oncology. 29:e16595-e16595
e16595 Background: Selection of adjuvant breast cancer (BC) therapy varies based on patient risk factors. Utilization and choice of chemotherapy (CT), schedule, duration, and supportive care affect...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::994da218cd4e3cda1917e216047d33b8
https://doi.org/10.1200/jco.2011.29.15_suppl.e16595
https://doi.org/10.1200/jco.2011.29.15_suppl.e16595
Autor:
Marcus A. Neubauer, Michael Kolodziej, Roy A. Beveridge, J. Flinn, Aimee Ginsburg, Thomas H. Cartwright, Leslie T. Busby, John Russell Hoverman, R. W. Anderson, Mark A. Sitarik, Barry Don Brooks, Debra A. Patt, US Oncology Pathways Task Force, Janet L. Espirito
Publikováno v:
Journal of Clinical Oncology. 29:e16526-e16526
e16526 Background: Male breast cancer (BC) affects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86d4ee96dc2776f3eeb7fd283926e5e3
https://doi.org/10.1200/jco.2011.29.15_suppl.e16526
https://doi.org/10.1200/jco.2011.29.15_suppl.e16526
Autor:
Thomas H. Cartwright, R. W. Anderson, Jody S. Garey, Roy A. Beveridge, Michael Kolodziej, Leslie T. Busby, Barry Don Brooks, Greg C. Nelson, Mark A. Sitarik, US Oncology Pathways Task Force, Marcus A. Neubauer, Debra A. Patt, John Russell Hoverman
Publikováno v:
Journal of Clinical Oncology. 29:e16527-e16527
e16527 Background: Bevacizumab (B) was FDA-approved in 2004 in combination with carboplatin and paclitaxel (CP) for treatment of first-line metastatic NSCLC after a phase III trial was conducted sh...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76494630c67e1b9544b64ec70455e000
https://doi.org/10.1200/jco.2011.29.15_suppl.e16527
https://doi.org/10.1200/jco.2011.29.15_suppl.e16527